Skip to main content

Advertisement

We’d like to understand how you use our websites in order to improve them. Register your interest.
Download PDF

Rationale, design and objectives of ARegPKD, a European ARPKD registry study

BMC Nephrology volume 16, Article number: 22 (2015) Cite this article

Abstract

Background

Autosomal recessive polycystic kidney disease (ARPKD) is a rare but frequently severe disorder that is typically characterized by cystic kidneys and congenital hepatic fibrosis but displays pronounced phenotypic heterogeneity. ARPKD is among the most important causes for pediatric end stage renal disease and a leading reason for liver-, kidney- or combined liver kidney transplantation in childhood. The underlying pathophysiology, the mechanisms resulting in the observed clinical heterogeneity and the long-term clinical evolution of patients remain poorly understood. Current treatment approaches continue to be largely symptomatic and opinion-based even in most-advanced medical centers. While large clinical trials for the frequent and mostly adult onset autosomal dominant polycystic kidney diseases have recently been conducted, therapeutic initiatives for ARPKD are facing the challenge of small and clinically variable cohorts for which reliable end points are hard to establish.

Methods/Design

ARegPKD is an international, mostly European, observational study to deeply phenotype ARPKD patients in a pro- and retrospective fashion. This registry study is conducted with the support of the German Society for Pediatric Nephrology (GPN) and the European Study Consortium for Chronic Kidney Disorders Affecting Pediatric Patients (ESCAPE Network). ARegPKD clinically characterizes long-term ARPKD courses by a web-based approach that uses detailed basic data questionnaires in combination with yearly follow-up visits. Clinical data collection is accompanied by associated biobanking and reference histology, thus setting roots for future translational research.

Discussion

The novel registry study ARegPKD aims to characterize miscellaneous subcohorts and to compare the applied treatment options in a large cohort of deeply characterized patients. ARegPKD will thus provide evidence base for clinical treatment decisions and contribute to the pathophysiological understanding of this severe inherited disorder.

Peer Review reports

Background

Autosomal recessive polycystic kidney disease (ARPKD) is a rare, but severe form of polycystic kidney disease with unexplained phenotypic variability and a considerable impact on affected patients and families as well as attending physicians. The disease is caused by mutations in a single gene, Polycystic Kidney and Hepatic Disease 1 (PKHD1) encoding a huge transmembrane protein of poorly understood function called fibrocystin (4074 amino acids) [1]. Fibrocystin localizes to primary cilia of cells, classifying ARPKD as ciliopathy [2].

Within the last years basic science approaches have brought tremendous progress in the understanding of the genetic basis and pathomechanisms of ciliopathies [2-5]. As a consequence first clinical trials on potential treatment approaches for the common adult-onset autosomal dominant polycystic kidney disease (ADPKD) have been conducted and have aroused much scientific attention [6-12]. Still, these trials have not yet established a clear-cut and safe general treatment therapy for ADPKD.

With an estimated incidence of 1 in 20.000 live births ARPKD is much rarer than ADPKD and lacks similar targeted therapeutic approaches. Furthermore, initiatives for randomized clinical trials on ARPKD are facing the difficulty of clinically highly variable cohorts for which reliable clinical study end points are hard to establish. The underlying molecular mechanisms of the observed clinical heterogeneity are currently poorly understood. Genotype-phenotype correlations are confined to an interrelation of two truncating mutations with a mostly severe phenotype with peri- or neonatal demise and the observation that most patients surviving the neonatal period carry at least one missense mutation as milder manifestation [13,14]. Mutations in modifier genes may be involved as it has been described in other ciliopathies [2]. Finally, PKHD1 is subject to a complex splicing pattern, adding another level of complexity to mechanisms controlling fibrocystin expression [15,16].

Clinically, the phenotypic spectrum of ARPKD ranges from severely affected newborns with a persisting high mortality of up to 30% often related to respiratory failure in pulmonary hypoplasia [17] to mild affected adults with predominant hepatic fibrosis.

Renal involvement in ARPKD is characterized by bilateral massive enlargement of the kidneys and microcystic kidney disease as a consequence of fusiform tubular dilatations usually deriving from the collecting duct. Kidney function deteriorates over time and kidney transplantation is required in up to 50% of patients within the first two decades of life [14].

Beneath renal involvement ARPKD obligatory encompasses congenital hepatic fibrosis (CHF) due to ductal plate malformation, with or without intrahepatic bile duct dilatation. Portal hypertension, potentially resulting in variceal bleeding, and cholangitis are leading clinical manifestations of liver involvement. Additional clinical manifestations include pronounced arterial hypertension, secondary pulmonary hypertension, and hyponatremia. For a detailed review of the broad spectrum of clinical manifestations we refer to the recent excellent review articles by Büscher et al. [18], Sweeney and Avner [19] and Hartung and Guay-Woodford [15].

Therapeutic management of the various challenging clinical problems is mainly based on the physician’s clinical experiences and from retrospective data or expert opinions, such as the recently published consensus recommendations on ARPKD treatment [20]. In summary, the management of ARPKD currently remains largely opinion-based.

Regarding the description of clinical courses we can refer to important previous studies by Guay-Woodford [17], Adeva [21] and Bergmann [14] who described American and European cohorts. Still, as previously pointed out, there are multiple remaining questions and despite the mentioned expert opinion recommendations [20], there is an urging need e.g. for evidence-based management guidelines and clinical descriptions of long-term follow-ups. Clinical or biochemical risk markers have not yet been established and current treatment approaches have not been systematically reviewed. Finally, the insights obtained from molecular studies on ciliopathies have opened a new understanding of the underlying pathomechanisms. These insights may sharpen our clinical view for subtle phenotypes and may help to classify defined subgroups of ARPKD patients in the future. As nicely pointed out by the Consortium for Radiologic Imaging Study of PKD (CRISP) in a very recent study, classification into different subgroups in ADPKD may have prognostic implications [22]. This may also apply for ARPKD.

To address these open questions on ARPKD two renowned clinical research consortia in pediatric nephrology, i.e. the German Society for Pediatric Nephrology (GPN) and the European Study Consortium for Chronic Kidney Disorders Affecting Pediatric Patients (ESCAPE Network) recently teamed up to start a joint initiative for a clinical registry study exclusively devoted to ARPKD. This registry study (ARegPKD) is now open for the inclusion of patients. Here, we present the details of ARegPKD for the first time.

Methods/Design

Study population

ARegPKD is an international, multicenter, pro- and retrospective, observational study in both pediatric and adult ARPKD patients. Inclusion criteria comprise the diagnosis of ARPKD by histology, molecular assessment or clinical evaluation according to the criteria of Zerres et al [23]. Those criteria are a) typical findings on renal imaging and b) one or more of the following criteria:

  • Clinical/laboratory signs of hepatic fibrosis

  • Hepatic pathology demonstrating ductal plate abnormality

  • Absence of renal enlargement and/or multiple cysts in both parents

  • Pathoanatomic diagnosis of ARPKD in an affected sibling

  • Family history consistent with autosomal recessive inheritance.

Definite genetic, histological or clinical proof of other cystic kidney disorders represents an exclusion criterion. Patient inclusion is preceded by informed consent and by approval of the registry study by a corresponding local ethics committee, thereby guaranteeing accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

Data handling

All data will be pseudonymously entered into a password-restricted web-based database on a safe server of the University of Cologne and secured by use of SSL-connections (www.aregpkd.org). Subject identification will only be possible at the local study site and participating centers are exclusively able to review and modify data of patients from the corresponding site. Transmitted data will be stored in the central database on a central and safe server at Cologne University Computing Facilities.

Data quality

In addition to automated entry checks using predefined plausibility ranges, mandatory statements regarding diagnosis criteria will minimize the risk for incomplete or erroneous data entries as well as inclusion of falsely diagnosed patients. Data entries will also be reviewed by a pediatric nephrologist at random checks and during regular interims analyses. Queries will be sent to the local investigators in cases of implausibility or doubt. In case of major problems with accomplishing regular local data entries, an associated regional coordinator in charge will provide support. Regional coordinators will be named for a group of centers.

Statistical analysis

Statistical analysis will mainly focus on descriptive analysis including calculation of relative and absolute frequencies for binary/categorical variables and for continuous variables calculation of mean, standard deviation, median, interquartile range, minimum and maximum. Inferential analyses will be planned based on first results of intermediate analyses and predefined in detail in a statistical analysis plan (SAP). Further longitudinal data regarding outcomes of markers of renal and hepatic function, overall survival and e.g. kidney size will be analyzed using appropriate statistical methods such as mixed modeling. In case of missing data appropriate methods (e.g. multiple imputation) will be used to handle them. Furthermore the aspect of multiple testing will be considered. Potential sources of bias will be examined and considered in the analyses.

Study organization and design

Data acquisition is partitioned in basic data and follow-up visits (Figure 1).

Figure 1
figure1

Study flow chart.

Full size image

  • *Basic data (Table 1)

    Table 1 Synopsis of data obtained in ARegPKD
    Full size table

Within the section of basic data details regarding clinical symptoms at primary manifestation are documented. Available results of genetic testing and family history data regarding cystic kidney disease as well as potential liver affection are included.

  • *Initial visit/follow-up visits (Table 1)

After completion of basic data the initial visit is created for enrollment of clinical, radiologic, laboratory and other findings of different organ systems (kidney, liver, spleen, cardiovascular system, lung, eye, central nervous system, other organs). A patient’s medication is documented with dose and application duration, surgical procedures are provided with date, indication and possible complications, and histological findings can be entered. Individual aspects not specifically requested in the questionnaire can be added as free text. At least yearly follow-ups with identical questionnaires provide data on the clinical course in a pro- or retrospective manner.

Biobanking

Blood and tissue samples shall be taken at every visit (both initial and/or follow-up visits). Initial blood samples include e.g. serum, plasma and EDTA blood. Yearly follow-up blood samples (e.g. serum, plasma) shall be collected if possible. Importantly, there will be no additional interventions or blood takings, material for storing will exclusively be obtained within routinely indicated examinations. Samples will be pseudonymously sent to Hannover Unified Biobank (HUB) the central biobank of Hannover Medical School. At HUB the biomaterials will be identified by a unique Lab-ID. HUB is one of the most modern biobanks in Europe. It is characterized by a high degree of automation and state-of-the-art biobank infrastructure according to standard operating procedures with data safety concepts, pseudonymization tools, sample identification via 2-D bar codes and integrated IT systems that will enable high quality and safety standards. Stable biobank structures, continuous temperature monitoring, emergency power supply, and 7/24 sample maintenance guarantee a high safety standard in the short- and long-term storage of biomaterials.

The samples from Turkey will be pseudonymously stored at Hacettepe Biobank at the Biobanking and Genomics Research and Application Center of the Hacettepe University.

Biosamples can be requested for basic research questions by written application to the ARegPKD steering committee and must include a proven positive ethics votum. Appropriation of biosamples will be restricted to research on cystic kidney diseases.

Reference histology

Reference histology of biopsy samples is offered by the Institute of Pathology of the University Hospital of Cologne. Professor Reinhard Buettner, chair of pathology at the University Hospital of Cologne, is an internationally recognized expert for ARPKD. In addition to the assessment of existing genetic analyses, reference histology evaluation complementing local histological examination can serve as an important factor to maintain highest security and standards concerning the correct diagnosis of ARPKD. Histologic evaluation will focus on the assessment of liver and kidney but will include, if available, samples from other organs. Histological samples will be scanned by a Mirax (Zeiss) slide scanner and uploaded to a central server connected to a web-based virtual histology discussion platform. This will save and store all histological samples in a pseudonymous fashion and make them available for discussion and inspection for all members of ARegPKD.

Ethics aspects

The study protocol including patient information and consent forms has been reviewed and approved by the Ethics Commission of the Faculty of Medicine of Cologne University. Corresponding local review boards are approached for confirmation of this approval.

Appropriate measures are used to guarantee maximal data confidentiality. All patient-related clinical data is pseudonymized locally. Blood samples are double-coded and neither laboratories nor the central office are able to identify individual patients.

Discussion

ARPKD is one of the most severe pediatric renal diseases presenting with a substantial and poorly understood phenotypic variability. Still, current management approaches remain opinion-based [20], clinical or biochemical markers for disease progression are missing, and long-term courses have not yet been reviewed in large cohorts.

To promote and elaborate our understanding of ARPKD, the GPN and the ESCAPE Network jointly initiated an international registry study to pool data regarding ARPKD clinical courses as well as different management approaches in European countries. This database is supposed to serve as a basis for translational research. Due to networking of two European consortia ARegPKD is expected to collect one of the largest cohorts of ARPKD patients with longitudinal data acquisition.

A prominent strength of the study will be the coverage of the major proportion of European ARPKD patients treated in highly specialized centers. Patients will be characterized in a pro- and retrospective manner with detailed questionnaires. We aim to get data for a deep phenotypical characterization that may help to identify specific subcohorts of ARPKD patients. Work by various independent groups addressed the question of potential differences in hepatic and renal disease progression in ARPKD [14,17,24]. Our data may also become helpful to give insights into this field.

Precise clinical characterization will be refined by establishing a concomitant ARPKD specific biobank and reference histology. This approach will set basis for translational and clinical research within a phenotypically deeply-defined international cohort of patients.

As a registry study, ARegPKD will have substantial limitations. Potential infirmities could arise from varying data quality with respect to completeness and accuracy of data, especially in case of retrospectively obtained data. Investigator-dependency may be an issue for clinical or radiologic examinations. Registered patients will furthermore show variable extent of genetic testing with multiple techniques; in some patients without genetic testing it may pose a difficulty to uncover phenotypic overlaps (“phenocopies”) with other polycystic kidney disorders. We will in most cases not have access to data on ARPKD-fetuses in case of induced termination of pregnancy. Finally, data may be missed or limited in cases of perinatal or early neonatal mortality contributing to a selection bias that will also be seen due to the character of the participating centers.

Factors influencing disease course like the development of end stage renal disease (ESRD) or hepatic insufficiency have not yet been established. Current clinical management focuses on symptomatic treatment in an opinion-based manner. We are therefore interested in long-term data regarding e.g. the time to ESRD and the effect of sufficient control of arterial hypertension on the deterioration of renal function. The frequently applied RAAS-blockade with angiotensin converting enzyme inhibitors or angiotensin receptor blockers is based on preliminary evidence from animal models [25-27] and from the data on the positive effect of strict blood pressure control on renal failure in children obtained in the ESCAPE study [28]. Still in this study only a minor fraction of patients suffered from ARPKD. The effect of different pharmacological antihypertensive classes on cyst respective kidney size and renal function remains to be elucidated as well as the proof of efficacy of antihypertensive therapy on slowing progression to end-stage-renal-disease in the ARPKD-cohort. Parameters with accelerating or slowing influence on development of renal failure are still to be identified in the ARPKD-cohort.

Additionally, we expect longitudinal data regarding the impact of uni- and bilateral nephrectomy on dialysis regimen and -efficacy, as well as data on the frequency of potentially recovering kidney function within the first year of life. As recently pointed out the currently available level of evidence on the effects of nephrectomy in ARPKD children is very limited [20]. Furthermore, single-center reports regarding outcomes of and indications for simultaneous vs. sequential liver and kidney transplantation in individuals with severe renal and hepatic phenotype [29-31] require analyses in a larger ARPKD cohort as basis for decision-making.

For the common ADPKD recent international clinical trials have studied the effect of different therapeutic approaches on total kidney volume (TKV) and renal function (mTOR inhibitors, vasopressin V2-receptor antagonists, somatostatin analogues, statin [6-10]). In these trials TKV serves as a surrogate parameter for disease progression as data from the CRISP study have shown that increased TKV is associated with worse outcome in ADPKD [32]. Similar attempts for clinical trials in ARPKD are missing. There is limited experimental data on the role of mTOR activation in ARPKD [33-36]. Animal data in PCK rats regarding vasopressin V2-receptor antagonism and its effect on reducing kidney weight and cyst volume is more robust [37,38]. The transfer of the data and studies regarding cyst growth in ADPKD on a cohort of ARPKD patients seems to be obvious and sonographic assessment of kidney length is used as a surrogate of TKV in the ARegPKD questionnaires. Still, this transfer is hampered by the fact, that TKV has not been established as an indicator of renal function deterioration in patients with ARPKD. Furthermore, TKV seems to be no good marker for kidney function in ARPKD patients as the most rapid growth of kidney volume is usually seen in the early disease course while no continuous volume gain is observed during progressive disease with loss of renal function. As TKV cannot be used potential clinical trials will therefore need to establish novel and specific clear-cut primary end points for ARPKD. ARegPKD aims to address this issue by detailed characterization of long term patient courses to set roots for the establishment of clinical trials on targeted treatment approaches.

In summary ARegPKD is a novel web-based international registry study aiming to provide evidence base for clinical treatment decisions and contributing to the understanding of ARPKD.

References

  1. 1.

    Ward CJ, Hogan MC, Rossetti S, Walker D, Sneddon T, Wang X, et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet. 2002;30:259–69.

  2. 2.

    Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. N Engl J Med. 2011;364:1533–43.

  3. 3.

    Fliegauf M, Benzing T, Omran H. When cilia go bad: cilia defects and ciliopathies. Nat Rev Mol Cell Biol. 2007;8:880–93.

  4. 4.

    Novarino G, Akizu N, Gleeson JG. Modeling human disease in humans: the ciliopathies. Cell. 2011;147:70–9.

  5. 5.

    Liebau MC. An emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases. Front Pediatr. 2014;2:68.

  6. 6.

    Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363:830–40.

  7. 7.

    Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363:820–9.

  8. 8.

    Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407–18.

  9. 9.

    Caroli A, Perico N, Perna A, Antiga L, Brambilla P, Pisani A, et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet. 2013;382:1485–95.

  10. 10.

    Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, et al. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2014;9:889–96.

  11. 11.

    Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2255–66.

  12. 12.

    Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2267–76.

  13. 13.

    Bergmann C, Senderek J, Sedlacek B, Pegiazoglou I, Puglia P, Eggermann T, et al. Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARPKD/PKHD1). J Am Soc Nephrol JASN. 2003;14:76–89.

  14. 14.

    Bergmann C, Senderek J, Windelen E, Küpper F, Middeldorf I, Schneider F, et al. Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD). Kidney Int. 2005;67:829–48.

  15. 15.

    Hartung EA, Guay-Woodford LM. Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects. Pediatrics. 2014;134(3):e833–45.

  16. 16.

    Boddu R, Yang C, O’Connor AK, Hendrickson RC, Boone B, Cui X, et al. Intragenic motifs regulate the transcriptional complexity of Pkhd1/PKHD1. J Mol Med (Berl). 2014;92(10):1045–56.

  17. 17.

    Guay-Woodford LM, Desmond RA. Autosomal recessive polycystic kidney disease: the clinical experience in North America. Pediatrics. 2003;111(5 Pt 1):1072–80.

  18. 18.

    Büscher R, Büscher AK, Weber S, Mohr J, Hegen B, Vester U, et al. Clinical manifestations of autosomal recessive polycystic kidney disease (ARPKD): kidney-related and non-kidney-related phenotypes. Pediatr Nephrol. 2014;29(10):1915–25.

  19. 19.

    Sweeney WE, Avner ED. Pathophysiology of childhood polycystic kidney diseases: new insights into disease-specific therapy. Pediatr Res. 2014;75:148–57.

  20. 20.

    Guay-Woodford LM, Bissler JJ, Braun MC, Bockenhauer D, Cadnapaphornchai MA, Dell KM, et al. Consensus expert recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease: report of an international conference. J Pediatr. 2014;165(3):611–7.

  21. 21.

    Adeva M, El-Youssef M, Rossetti S, Kamath PS, Kubly V, Consugar MB, et al. Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine (Baltimore). 2006;85:1–21.

  22. 22.

    Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol JASN. 2015;26(1):160–72.

  23. 23.

    Zerres K, Rudnik-Schöneborn S, Deget F, Holtkamp U, Brodehl J, Geisert J, et al. Autosomal recessive polycystic kidney disease in 115 children: clinical presentation, course and influence of gender. Arbeitsgemeinschaft für Pädiatrische, Nephrologie. Acta Paediatr Oslo Nor 1992. 1996;85:437–45.

  24. 24.

    Gunay-Aygun M, Font-Montgomery E, Lukose L, Tuchman Gerstein M, Piwnica-Worms K, Choyke P, et al. Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease. Gastroenterology. 2013;144:112–21. e2.

  25. 25.

    Jia G, Kwon M, Liang HL, Mortensen J, Nilakantan V, Sweeney WE, et al. Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease. Pediatr Nephrol. 2010;25:1139–46.

  26. 26.

    Goto M, Hoxha N, Osman R, Wen J, Wells RG, Dell KM. Renin-angiotensin system activation in congenital hepatic fibrosis in the PCK rat model of autosomal recessive polycystic kidney disease. J Pediatr Gastroenterol Nutr. 2010;50:639–44.

  27. 27.

    Goto M, Hoxha N, Osman R, Dell KM. The renin-angiotensin system and hypertension in autosomal recessive polycystic kidney disease. Pediatr Nephrol. 2010;25:2449–57.

  28. 28.

    ESCAPE Trial Group, Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009;361:1639–50.

  29. 29.

    Chapal M, Debout A, Dufay A, Salomon R, Roussey G, Burtey S, et al. Kidney and liver transplantation in patients with autosomal recessive polycystic kidney disease: a multicentric study. Nephrol Dial Transplant. 2012;27:2083–8.

  30. 30.

    Brinkert F, Lehnhardt A, Montoya C, Helmke K, Schaefer H, Fischer L, et al. Combined liver-kidney transplantation for children with autosomal recessive polycystic kidney disease (ARPKD): indication and outcome. Transpl Int. 2013;26:640–50.

  31. 31.

    Srinath A, Shneider BL. Congenital hepatic fibrosis and autosomal recessive polycystic kidney disease. J Pediatr Gastroenterol Nutr. 2012;54:580–7.

  32. 32.

    Torres VE, King BF, Chapman AB, Brummer ME, Bae KT, Glockner JF, et al. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol CJASN. 2007;2:112–20.

  33. 33.

    Renken C, Fischer D-C, Kundt G, Gretz N, Haffner D. Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats. Nephrol Dial Transplant. 2011;26:92–100.

  34. 34.

    Ren XS, Sato Y, Harada K, Sasaki M, Furubo S, Song JY, et al. Activation of the PI3K/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat. PLoS One. 2014;9:e87660.

  35. 35.

    Sabbatini M, Russo L, Uccello F, Iaccarino A, Pisani A. Clinical treatment of polycystic kidney disease (APKD): do we need further suggestions from rodents? Nephrol Dial Transplant. 2011;26:2065–6.

  36. 36.

    Stayner C, Shields J, Slobbe L, Shillingford JM, Weimbs T, Eccles MR. Rapamycin-mediated suppression of renal cyst expansion in del34 Pkd1-/- mutant mouse embryos: an investigation of the feasibility of renal cyst prevention in the foetus. Nephrol Carlton Vic. 2012;17:739–47.

  37. 37.

    Gattone VH, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9:1323–6.

  38. 38.

    Wang X, Gattone V, Harris PC, Torres VE. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol JASN. 2005;16:846–51.

Download references

Acknowledgments

We thank GPN and ESCAPE for the support. M.C.L. was supported by grants of the GPN, the European Society for Paediatric Nephrology, the German PKD foundation, the Koeln Fortune program, the GEROK program of the Medical Faculty of University of Cologne, and the Marga and Walter Boll-Foundation. The Pediatric Study Center Cologne was supported by the German Federal Ministry of Research and Education (BMBF grant 01KN1106).

Author information

Affiliations

  1. Department of Pediatrics, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany
    • Kathrin Ebner
    • , Barbara Hero
    • , Lutz Thorsten Weber
    • , Jörg Dötsch
    •  & Max Christoph Liebau
  2. Department of Pediatrics, University Hospital Bonn, Adenauerallee 119, 53113, Bonn, Germany
    • Markus Feldkoetter
    •  & Bernd Hoppe
  3. Department of Pediatric Nephrology, University Hospital Vall d’Hebron, Pg/Vall d’ Hebron 119-129, 08034, Barcelona, Spain
    • Gema Ariceta
  4. Bioscientia Center for Human Genetics, Konrad-Adenauer-Straße 17, 55218, Ingelheim, Germany
    • Carsten Bergmann
  5. Renal Division, Department of Medicine, University Freiburg Medical Center, Hugstetter Straße 55, 79106, Freiburg, Germany
    • Carsten Bergmann
  6. Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany
    • Reinhard Buettner
    •  & Heike Goebel
  7. Division of Pediatric Nephrology, University Children’s Hospital Heidelberg, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany
    • Anke Doyon
    •  & Franz Schaefer
  8. Department of Pediatrics, Division of Pediatric Nephrology, Hacettepe University Faculty of Medicine, Sihhiye, 06100, Ankara, Turkey
    • Ali Duzova
  9. Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany
    • Dieter Haffner
  10. Hannover Unified Biobank, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany
    • Thomas Illig
    •  & Norman Klopp
  11. Institute for Human Genetics, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany
    • Thomas Illig
  12. Vilnius University Hospital, Center for Pediatrics, Santariskiu, 08406, Vilnius, Lithuania
    • Augustina Jankauskiene
  13. Department of General Pediatrics, University Hospital Münster, Waldeyerstr. 22, 48149, Muenster, Germany
    • Jens König
  14. The Children’s Memorial Health Institute, Al. Dzieci Polskich 20, 04-730, Warsaw, Poland
    • Mieczyslaw Litwin
    •  & Dorota Wicher
  15. Department of Pediatric Nephrology, University Hospitals Leuven, Herestrtaat 49, 3000, Leuven, Belgium
    • Djalila Mekahli
  16. Service de Néphrologie Pédiatrique, Hospices Civils de Lyon, Université de Lyon, Hôpital Femme Mère Enfant, 69677, Bron, France
    • Bruno Ranchin
  17. Institute of Medical Biometry and Informatics, University of Heidelberg, Im Neuenheimer Feld 305, 69120, Heidelberg, Germany
    • Anja Sander
  18. Pediatric Nephrology Unit, Fondazione IRCCS Ca Granda Ospedale Maggiore Polic, Via della Commenda 9, 20122, Milano, Italy
    • Sara Testa
  19. Department of Medical Biology, Center for Biobanking and Genomics, Hacettepe University, Ankara, Turkey
    • Ayse Yuzbasioglu
  20. Institute of Human Genetics, RWTH University Hospital Aachen, Pauwelsstrasse 30, 52074, Aachen, Germany
    • Klaus Zerres
  21. Center for Molecular Medicine, University Hospital of Cologne, Robert-Koch-Str. 21, 50931, Cologne, Germany
    • Max Christoph Liebau
  22. Nephrology Research Laboratory, Department II of Internal Medicine, University Hospital of Cologne, CECAD Building, Joseph-Stelzmann-Str. 26, 50931, Cologne, Germany
    • Max Christoph Liebau
Authors
  1. Kathrin Ebner
    View author publications
    You can also search for this author in
  2. Markus Feldkoetter
    View author publications
    You can also search for this author in
  3. Gema Ariceta
    View author publications
    You can also search for this author in
  4. Carsten Bergmann
    View author publications
    You can also search for this author in
  5. Reinhard Buettner
    View author publications
    You can also search for this author in
  6. Anke Doyon
    View author publications
    You can also search for this author in
  7. Ali Duzova
    View author publications
    You can also search for this author in
  8. Heike Goebel
    View author publications
    You can also search for this author in
  9. Dieter Haffner
    View author publications
    You can also search for this author in
  10. Barbara Hero
    View author publications
    You can also search for this author in
  11. Bernd Hoppe
    View author publications
    You can also search for this author in
  12. Thomas Illig
    View author publications
    You can also search for this author in
  13. Augustina Jankauskiene
    View author publications
    You can also search for this author in
  14. Norman Klopp
    View author publications
    You can also search for this author in
  15. Jens König
    View author publications
    You can also search for this author in
  16. Mieczyslaw Litwin
    View author publications
    You can also search for this author in
  17. Djalila Mekahli
    View author publications
    You can also search for this author in
  18. Bruno Ranchin
    View author publications
    You can also search for this author in
  19. Anja Sander
    View author publications
    You can also search for this author in
  20. Sara Testa
    View author publications
    You can also search for this author in
  21. Lutz Thorsten Weber
    View author publications
    You can also search for this author in
  22. Dorota Wicher
    View author publications
    You can also search for this author in
  23. Ayse Yuzbasioglu
    View author publications
    You can also search for this author in
  24. Klaus Zerres
    View author publications
    You can also search for this author in
  25. Jörg Dötsch
    View author publications
    You can also search for this author in
  26. Franz Schaefer
    View author publications
    You can also search for this author in
  27. Max Christoph Liebau
    View author publications
    You can also search for this author in

Consortia

ESCAPE Study Group

GPN Study Group

Corresponding author

Correspondence to Max Christoph Liebau.

Additional information

Competing interests

CB is an employee of Bioscientia/Sonic Healthcare. The other authors declare that they have no competing interests.

Authors’ contributions

KE and MCL drafted the manuscript. MF, CB, RB, ADu, DH, BHe, BHo, AJ, JK, ML, BR, ST, KZ, JD, FS, and MCL designed the study. MCL, MF, AS, BHe and JD designed the study protocol. KE, GA, ADu, ADo, AJ, ML, DM, BR, ST, LTW, DW, FS and MCL contribute to coordinated European establishment of the study. RB, HG, NK, TI, and AY coordinate reference histology and biobanking, respectively. All authors reviewed and approved the final manuscript.

Authors’ information

Collaborators: F. Cachat (Lausanne, Switzerland), T. Seeman (Prague, Czech Republic), N. Ortiz Bruechle (Aachen, Germany), U. Querfeld (Berlin, Germany), M. Kirschstein (Celle, Germany), K. Benz (Erlangen), R. Buescher (Essen, Germany), K. Latta (Frankfurt, Germany), M. Pohl (Freiburg, Germany), O. Gross (Goettingen, Germany), L. Patzer (Halle/Saale, Germany), M. Kemper (Hamburg, Germany), L. Pape (Hannover, Germany), W. Bernhardt (Hannover, Germany), E. Wuehl (Heidelberg, Germany), B. Beck (Cologne, Germany), T. Benzing (Cologne, Germany) S. Wygoda (Leipzig, Germany), D. Wiemann (Magdeburg, Germany), G. Klaus (Marburg, Germany), H. Fehrenbach (Memmingen, Germany), M. Wallot (Moers, Germany), B. Lange-Sperandio (Munich, Germany), B. Uetz (Munich, Germany), B. Kranz (Muenster, Germany), M. Boeswald (Muenster, Germany), H. Staude (Rostock, Germany), H.E. Leichter (Stuttgart, Germany), H. Billing (Tuebingen, Germany), O. Beringer (Ulm, Germany), M.-L. Ilmoja (Tallinn, Estonia), L. E. Lara (Barcelona, Spain) P. Sallay (Budapest, Hungary), G. Ardissino (Milano, Italy), F. Emma (Rome, Italy), R. Cerkauskiene (Vilnius, Lithuania), D. Drozdz (Krakow, Poland), A. Niemirska (Warsaw, Poland), M. Szczepanska (Zabrze, Poland), M. Zaniew (Poznan Poland), D. Paripović (Belgrade, Serbia), A. Anarat (Adana, Turkey), E. Baskin (Ankara, Turkey), S. Caliskan (Istanbul, Turkey), C. Candan (Istanbul, Turkey), S. Emre (Istanbul, Turkey), I. Dursun (Kayseri, Turkey), Z. Ekinci (Kocaeli, Turkey), A. Delibas (Mersin, Turkey), L. Kerecuk (Birmingham, United Kingdom), L. Guay-Woodford (Washington, USA).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ebner, K., Feldkoetter, M., Ariceta, G. et al. Rationale, design and objectives of ARegPKD, a European ARPKD registry study. BMC Nephrol 16, 22 (2015). https://doi.org/10.1186/s12882-015-0002-z

Download citation

Keywords

  • ARPKD
  • Ciliopathy
  • PKHD1
  • Polycystic kidney disease
  • Congenital hepatic fibrosis

BMC Nephrology

ISSN: 1471-2369

Contact us